Soria JC - Search Results

1

Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trial.

Bahleda R, Massard C, Soria JC, Izzedine H, Cohen A, Ederhy S. Bahleda R, et al. Among authors: soria jc. Invest New Drugs. 2010 Jun;28(3):350-2. doi: 10.1007/s10637-009-9252-6. Epub 2009 Apr 25. Invest New Drugs. 2010. PMID: 19396400

2

DNA G-quadruplexes, telomere-specific proteins and telomere-associated enzymes as potential targets for new anticancer drugs.

Raymond E, Soria JC, Izbicka E, Boussin F, Hurley L, Von Hoff DD. Raymond E, et al. Among authors: soria jc. Invest New Drugs. 2000 May;18(2):123-37. doi: 10.1023/a:1006373812586. Invest New Drugs. 2000. PMID: 10857992 Review.

3

[Therapeutic implications of epidermal growth factor receptor in lung cancer].

Fayette J, Le Chevalier T, Soria JC. Fayette J, et al. Among authors: soria jc. Bull Cancer. 2003 Nov;90 Spec No:S233-40. Bull Cancer. 2003. PMID: 14763145 Review. French.

4

Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy.

Loriot Y, Perlemuter G, Malka D, Penault-Llorca F, Boige V, Deutsch E, Massard C, Armand JP, Soria JC. Loriot Y, et al. Among authors: soria jc. Nat Clin Pract Oncol. 2008 May;5(5):268-78. doi: 10.1038/ncponc1087. Epub 2008 Mar 18. Nat Clin Pract Oncol. 2008. PMID: 18349858 Review.

5

Rhinitis and epistaxis in patients treated by anti-angiogenic therapy.

Prulière-Escabasse V, Escudier E, Balheda R, Soria JC, Coste A, Massard C. Prulière-Escabasse V, et al. Among authors: soria jc. Invest New Drugs. 2009 Jun;27(3):285-6. doi: 10.1007/s10637-008-9168-6. Epub 2008 Aug 27. Invest New Drugs. 2009. PMID: 18754078

6

Management of hypertension in angiogenesis inhibitor-treated patients.

Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP. Izzedine H, et al. Among authors: soria jc. Ann Oncol. 2009 May;20(5):807-15. doi: 10.1093/annonc/mdn713. Epub 2009 Jan 15. Ann Oncol. 2009. PMID: 19150949 Free article. Review.

7

Wound healing delay after central venous access following DCF/VEGF-trap therapy.

Ferté C, Massard C, Moldovan C, Desruennes E, Loriot Y, Soria JC. Ferté C, et al. Among authors: soria jc. Invest New Drugs. 2009 Dec;27(6):583-5. doi: 10.1007/s10637-009-9227-7. Epub 2009 Feb 17. Invest New Drugs. 2009. PMID: 19221694

8

From theoretical synergy to clinical supra-additive toxicity.

Soria JC, Massard C, Izzedine H. Soria JC, et al. J Clin Oncol. 2009 Mar 20;27(9):1359-61. doi: 10.1200/JCO.2008.20.8595. Epub 2009 Feb 17. J Clin Oncol. 2009. PMID: 19224836 No abstract available.

9

Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case report.

Gombos A, Izzedine H, Besse B, Massard C, Brocheriou I, Bahleda R, Soria JC. Gombos A, et al. Among authors: soria jc. Invest New Drugs. 2010 Feb;28(1):102-5. doi: 10.1007/s10637-009-9247-3. Epub 2009 Apr 3. Invest New Drugs. 2010. PMID: 19343274

10

Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour.

Domont J, Massard C, Lassau N, Armand JP, Le Cesne A, Soria JC. Domont J, et al. Among authors: soria jc. Invest New Drugs. 2010 Apr;28(2):199-202. doi: 10.1007/s10637-009-9249-1. Epub 2009 Apr 8. Invest New Drugs. 2010. PMID: 19352594 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

736 results

Search Page

Filters